麻风病

World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

World Health Organization. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982;675:1-33.

• 摘要

World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.

• 全文

World Health Organization. Chemotherapy of leprosy: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;847:1-24.

• 全文
• 摘要

WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.

• 全文
• 摘要

1.  World Health Organization Action Programme for the Elimination of Leprosy. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva: World Health Organization; 1997. WHO/LEP/97.7.

2.  Ridley DS Jopling.WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255-273.

• 摘要

3.  World Health Organization. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982;675:1-33.

• 摘要

4.  World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: Development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.

• 全文

5.  World Health Organization. Chemotherapy of leprosy: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;847:1-24.

• 全文
• 摘要

6.  Han XY, Jessurun J. Severe leprosy reactions due to Mycobacterium lepromatosis. Am J Med Sci. 2013;345:65-9.

• 全文
• 摘要

7.  Kamath S, Vaccaro SA, Rea TH, et al. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol. 2014;71:795-803.

• 摘要

8.  World Health Organization - Global Leprosy Programme. Global leprosy strategy 2016-2020. Accelerating towards a leprosy-free world. 2016. SEA-GLP-2016. http://www.searo.who.int/ (last accessed 1 July 2016).

• 全文

9.  Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409:1007-1011.

• 全文
• 摘要

10.  Han XY, Sizer KC, Tan HH. Identification of the leprosy agent Mycobacterium lepromatosis in Singapore. J Drugs Dermatol. 2012;11:168-172.

• 摘要

11.  Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338-381.

• 全文
• 摘要

12.  Rees RJ, McDougall AC. Airborne infection with Mycobacterium leprae in mice. J Med Microbiol. 1977;10:63-68.

• 摘要

13.  Chehl S, Job CK, Hastings RC. Transmission of leprosy in nude mice. Am J Trop Med Hyg. 1985;34:1161-1166.

• 摘要

14.  Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254:277-279.

• 摘要

15.  Mira MT, Alcaïs A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427:636-640.

• 摘要

16.  Misch EA, Berrington WR, Vary JC Jr, et al. Leprosy and the human genome. Microbiol Mol Biol Rev. 2010;74:589-620.

• 全文
• 摘要

17.  Guinto RS, Rodriguez JN, Doull JA, et al. The trend of leprosy in Cordova and Talisay, Cebu Province, Philipines. Int J Lepr. 1954;22:409-430.

• 摘要

18.  Noordeen SK, Neelan PN. Extended studies on chemoprophylaxis against leprosy. Indian J Med Res. 1978;67:515-527.

• 摘要

19.  Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364:1626-1633.

• 全文
• 摘要

20.  Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348:17-24.

• 摘要

21.  Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet. 1992;339:446-450.

• 摘要

22.  Gupte MD, Vallishayee RS, Anantharaman DS, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr. 1998;70:369-388.

• 摘要

23.  Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6:162-170.

• 摘要

24.  Zodpey SP. Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis. Indian J Dermatol Venereol Leprol. 2007;73:86-93.

• 摘要

25.  Zodpey SP. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health. 2004;48:70-77.

• 摘要

26.  Kartikeyan S, Chaturvedi RM, Deo MG. Anti-leprosy vaccines: current status and future prospects. J Postgrad Med. 1991;37:198-204.

• 全文
• 摘要

27.  Montestruc E, Berdonneau R. Two cases of leprosy in infants in Martinique [in French]. Bull Soc Pathol Exot Filiales. 1954;47:781-783.

• 摘要

28.  Van Veen NH, Nicholls PG, Smith WC, et al. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev. 2007;(2):CD005491.

• 摘要

29.  WHO Expert Committee on Leprosy. 7th report. World Health Organ Tech Rep Ser. 1998;874:20.

• 全文
• 摘要

30.  Manickam P, Nagaraju B, Selvaraj V, et al; Team of Study Investigators. Efficacy of single-dose chemotherapy (rifampicin, oflaxacin and minocycline-ROM) in PB leprosy patients with 2 to 5 skin lesions, India: randomised double-blind trial. Indian J Lepr. 2012;84:195-207.

• 摘要

31.  Cunha Mda G, Virmond M, Schettini AP, et al. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil. Lepr Rev. 2012;83:261-268.

• 摘要

32.  International Leprosy Association. Report of the International Leprosy Association Technical Forum: Paris, France, 22-28 February 2002. Int J Lepr Other Mycobact Dis. 2002;70(suppl):S1-S62.

• 摘要

33.  Consigny S, Bentoucha A, Bonnafous P, et al. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2000;44:2919-2921.

• 全文
• 摘要

34.  Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227.

• 摘要

35.  WHO Expert Committee on Leprosy. 8th report. World Health Organ Tech Rep Ser. 2012;968:1-61.

• 全文
• 摘要

36.  Goto M, Nogami R, Hatano K, et al. Guideline for the treatment of Hansen's disease in Japan (2nd edition). [Article in Japanese.] Nihon Hansenbyo Gakkai Zasshi. 2006;75:191-226.

• 摘要

37.  International Federation of Anti-Leprosy Associations. How to prevent disability in leprosy. ILEP learning guide 4. 2006. http://www.ilep.org.uk (last accessed 6 July 2016).

• 全文